Oncology

Treatment‑naive transformed DLBCL shows worse PFS driven by early progression

In a retrospective cohort of 1,735 treatment‑naive DLBCL patients, transformed DLBCL (trDLBCL) had inferior PFS versus de novo disease (multivariable HR 1.754, p<0.001). A 1:1 propensity‑matched analysis (108 pairs) confirmed worse PFS for trDLBCL, while overall survival was similar (p = 0.99). Pure transformation carried worse PFS and OS versus concurrent transformation (PFS p = 0.005; OS HR 2.56, p = 0.02). Early progression risk (POD24) was higher in trDLBCL (30.56% vs 18.52%; OR 1.94), and CNS involvement was low and comparable between groups. 1

Dietary interventions show heterogeneous effects on HRQoL during breast cancer therapy

This systematic review included 11 studies (9 randomized) assessing dietary interventions for women receiving chemotherapy and radiotherapy for breast cancer. Results were inconsistent across diets and HRQoL domains, with the strongest signals in gastrointestinal‑related QoL measures. Authors conclude evidence is limited and heterogeneous, supporting personalized dietary strategies rather than one universal diet. 2

Poor concordance between clinician CTCAE and patient‑reported symptoms in adjuvant chemotherapy

In 1,566 patients from the randomized PANTHER trial, agreement between clinician CTCAE grades and patient EORTC symptom scores was low (kappa 0.07–0.34). Clinicians systematically graded symptoms lower than patients, with largest discrepancies for fatigue (36%–54%) and pain (23%–38%). Discrepancies increased from mid‑ to end‑treatment for most domains, arguing for routine patient‑reported symptom collection. 3